• Regulatory NewsRegulatory News

    MHRA awards first ‘innovation passport’ under new pathway

    Merck’s investigational drug belzutifan on Friday became the first drug to be awarded an “innovation passport” under the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) innovative licensing and access pathway (ILAP).   Belzutifan is being developed to treat adults with von Hippel-Lindau disease, a rare cancer-causing genetic disorder, and has been granted orphan designation in the EU and both orphan designation and breakthrough therapy designation b...
  • Regulatory NewsRegulatory News

    England and Canada diverge from US on cancer drug decisions

    Regulatory and health technology assessment agencies in Canada and England are diverging from the US when it comes to oncology drugs. But they often rely on the same surrogate endpoints to make their decisions, according to two new analyses published in JAMA Internal Medicine .   The first study , led by Avi Cherla, MSc, of the London School of Economics and Political Science, revealed that among 68 cancer indications with accelerated approval in the US that also rec...
  • Regulatory NewsRegulatory News

    EMA, MHRA update on COVID vaccine pharmacovigilance

    Regulators in Europe are beginning to give safety readouts from global experiences with vaccines against COVID-19, while the United Kingdom has issued a report delineating its multi-pronged safety surveillance approach.   The European Medicines Agency’s safety committee met at the end of January to review data from clinical use of the COVID-19 messenger RNA (mRNA) vaccine co-developed by Moderna and the US National Institutes of Health.   Following a 28 January mee...
  • Regulatory NewsRegulatory News

    MHRA okays third COVID-19 vaccine

    As the first week of the new year winds down, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a third vaccine against COVID-19. On Friday, MHRA announced its regulatory approval of the messenger RNA (mRNA) vaccine jointly developed by Moderna and the US National Institutes of Health.   “Having a third COVID-19 vaccine approved for supply following a robust and thorough assessment of all the available data is an important goal to have ac...
  • Regulatory NewsRegulatory News

    What’s in the Brexit trade deal for the pharmaceutical and medical device industries?

    After years of painstaking negotiations, the UK parted ways with the EU on 1 January after an 11-month transition period with a 1,200-plus page trade deal in hand, narrowly avoiding a no-deal scenario.   The trade deal, which was reached on 24 December, avoids tariffs and quotas on goods traded between the EU and UK and sets forth some provisions for cooperation and alignment on a range of issues from transportation to environmental protection but avoids major topics...
  • Regulatory NewsRegulatory News

    UPDATED: UK authorizes Oxford-AstraZeneca COVID-19 vaccine

    Editor’s note: This article was updated 04 January 2020 to include new information about EMA's review of the Oxford-AstraZeneca COVID-19 vaccine.   The United Kingdom has followed the recommendation of its Medicines and Healthcare products Regulatory Agency (MHRA) to issue temporary authorization for the vaccine against COVID-19 co-developed by Oxford University and AstraZeneca. The UK’s authorization is the first for the vaccine.   The authorization for temporar...
  • Regulatory NewsRegulatory News

    Sponsors get RWE guidance from MHRA

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a draft guidance on the use of real-world evidence in clinical trials. The guidance, which remains open for consultation for 6 weeks from its 30 October publication date, is intended for sponsors planning clinical research in support of regulatory decisions.   MHRA notes that real-world evidence (RWE) may help investigators get at how a treatment will really work when it is in community use ...
  • Regulatory NewsRegulatory News

    MHRA issues post-transition orphan, Northern Ireland supply guidance

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday issued post-transition guidance on orphan medicines designations and incentives, as well as guidance on supplying medicines from Great Britain to Northern Ireland.   The guidances are the latest in a suite of post-transition guidance from the agency as it prepares for the Brexit transition period to expire at the end of the year. (RELATED: MHRA posts suite of post-transition guidances , ...
  • RoundupsRoundups

    Euro Roundup: UK, EU trade groups push Brexit negotiators to act to stop supply disruption

    Trade bodies representing the UK and European Union pharmaceutical industries have urged Brexit negotiators to act now to prevent disruption to the supply of medicines. The joint statement warns failing to form a mutual recognition agreement to soften a hard Brexit could cost both sides billions and delay the supply of medicines by up to six weeks.   The latest round of negotiations about the post-Brexit relationship between the UK and EU is due to end on Friday. If su...
  • Regulatory NewsRegulatory News

    Pharmacovigilance and QPPV: Post-transition guidance from MHRA

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) this week issued guidance detailing post-transition pharmacovigilance procedures and requirements for having a qualified person responsible for pharmacovigilance (QPPV) and a pharmacovigilance system master file (PSMF) for UK authorized products.   Pharmacovigilance   MHRA says it “will retain responsibility for pharmacovigilance across the UK from 1 January 2021,” but notes that there will be di...
  • Regulatory NewsRegulatory News

    MHRA: Post-transition guidance on licensing medicines

    In its suite of post-transition guidances released Tuesday, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a dozen documents explaining how medicines licensure will work after the Brexit transition period expires on 1 January 2021.   The guidance, which largely mirrors the “no deal” scenario laid out in now-withdrawn guidance issued last year, explains a range of issues from converting centrally authorized products (CAPs) to UK marketing au...
  • Regulatory NewsRegulatory News

    MHRA posts suite of post-transition guidances

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday released more than two dozen guidance documents explaining how drugs, medical devices, clinical trials and more will be regulated after the Brexit transition period expires on 1 January 2021.   Clinical trials   Two guidances related to clinical trials explain requirements for the registration of clinical trials for investigational medicinal products and the submission of substantial ...